gemtuzumab ozogamicin

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/04/15 00:53:30」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
  • Amadori S1, Suciu S2, Selleslag D2, Aversa F2, Gaidano G2, Musso M2, Annino L2, Venditti A2, Voso MT2, Mazzone C2, Magro D2, De Fabritiis P2, Muus P2, Alimena G2, Mancini M2, Hagemeijer A2, Paoloni F2, Vignetti M2, Fazi P2, Meert L2, Ramadan SM2, Willemze R2, de Witte T2, Baron F2.
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.
  • PURPOSE: To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy.PATIENTS AND METHODS: In this trial, patients at least 61 years old were central
  • PMID 26811524
  • The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
  • Kell J1.
  • Expert review of anticancer therapy.Expert Rev Anticancer Ther.2016 Mar 4. [Epub ahead of print]
  • The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemothe
  • PMID 26942450
  • Optimal treatment strategies for high-risk acute promyelocytic leukemia.
  • Norsworthy KJ1, Altman JK.
  • Current opinion in hematology.Curr Opin Hematol.2016 Mar;23(2):127-36. doi: 10.1097/MOH.0000000000000215.
  • PURPOSE OF REVIEW: Despite major advances in the treatment of acute promyelocytic leukemia (APL), high-risk APL still poses unique challenges. The purpose of this review is to outline current evidence for evaluation and management of high-risk APL and discuss areas of ongoing and future investigatio
  • PMID 26825698

Japanese Journal

  • 再発・難治APLに対するGO monotherapy
  • 注目の領域 米国での医薬品迅速承認制度の現状と課題 : midodrine,gemtuzumab ozogamicin,bevacizumabを例に
  • 太田 有子,天沼 喜美子,青木 良子 [他]
  • 医学のあゆみ 242(8), 612-620, 2012-08-25
  • NAID 40019381359
  • 急性骨髄性白血病(AML)に対するgemtuzumab ozogamicinの臨床的有用性に関する最近の考え方

Related Links

再発性・難治性骨髄性白血病の治療薬のMylotarg (Gemtuzumab Ozogamicin)についての解説です。日本では未認可ですが、認可されている米国から個人輸入で使用が可能ですので紹介しています。掲載内容は ...
The latest Tweets from アリアハンの勇者 (@Gemtuzumab). 楽しい世界を夢見て ... あぁーーほんっと腹立つわ!! むかつく客ばっかでほんと死んでほしい!!(笑) おとなのくせに何百円単位の返品でガタガタぬかしやがってよー。

Related Pictures

Gemtuzumab ozogamicin (Mylotarg) may have Gemtuzumab ozogamicin: Information from Gemtuzumab ozogamicin: Information from  of AML cells to gemtuzumab ozogamicinGemtuzumab ozogamicin (Mylotarg®; Pfizer Mylotarg® (gemtuzumab ozogamicin for